The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunological study.
Clinical, immunological, immunophenotypical, pathological and molecular biological studies were performed on tumor infiltrating lymphocytes (TIL) and lymph node lymphocytes (LN-ly) of 8 patients with squamous cell carcinoma of the oral cavity and oropharynx treated with 10 daily locoregional injections of low doses of IL-2 before surgery. No complications were seen during or after surgery. In 3 cases the LN-ly showed a moderate LAK activity, higher in the LN-ly omolateral to the tumor and near the IL-2 injection site; in 2 of these 3 patients a good LAK activity was induced after 6-day culture with IL-2. The LN-ly derived from nodes next to the tumor showed a decreased NK activity and proliferative ability both in basal conditions and after in vitro lymphokine challenging. LN-ly of 2 IL-2 treated patients showed high levels of mRNA encoding for IL-2-R, while it was absent in 2 untreated cases. Immunophenotypical studies on TIL showed statistically improved levels of CD25+ and LAK1+ cells in treated cases. Clusters of CD11c+ (macrophages) cells were seen close to the neoplastic sheets.
Cortesina
G
G
E.N.T. Department, University of Torino, Italy.
De Stefani
A
A
Galeazzi
E
E
Bussi
M
M
Giordano
C
C
Cavallo
G P
GP
Jemma
C
C
Vai
S
S
Forni
G
G
Valente
G
G
D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology; D007694:Killer Cells, Natural / Q000502:physiology; D008198:Lymph Nodes / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D010865:Pilot Projects; D011292:Premedication; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D015703:Antigens, CD; D007376:Interleukin-2; D011994:Recombinant Proteins